Court Can't Block Nonfinal Compounding Policy, FDA Says
Par Pharmaceutical is being premature by asking a D.C. federal court to enjoin a nonfinal policy regarding whether drugs like Par's blood pressure medication vasopressin can be compounded by outside companies,...To view the full article, register now.
Already a subscriber? Click here to view full article